Herein, in the current work, we studied whether JOA affect the differentiation blockade of imatinib-resistant CML cells carrying BCR-ABL-T315I mutation. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.